DEST.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 11:29):

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom...

Stats
Today's Volume	184 683
Average Volume	453 780
Market Cap	20.49M
EPS	£0 ( 2024-04-10 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-2.69
ATR14	£0.241 (1.14%)

Destiny Pharma PLC Correlation

10 Most Positive Correlations
WINE.L	0.9
GHT.L	0.889
INDV.L	0.883
DPEU.L	0.873
ONC.L	0.859
MCM.L	0.853
RMMC.L	0.842
UPGS.L	0.834
RWS.L	0.833
DGN.L	0.829

10 Most Negative Correlations
CMET.L	-0.851
PEN.L	-0.827
CAMB.L	-0.818
EUZ.L	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Destiny Pharma PLC Financials

Annual	2022
Revenue:	£154 499
Gross Profit:	£142 171 (92.02 %)
EPS:	£-0.0926

Q2	2023
Revenue:	£831 552
Gross Profit:	£827 883 (99.56 %)
EPS:	£-0.0309

Q4	2022
Revenue:	£154 499
Gross Profit:	£148 532 (96.14 %)
EPS:	£-0.0452

Q2	2022
Revenue:	£0
Gross Profit:	£-6 361.00 (0.00 %)
EPS:	£-0.0479

Financial Reports:

No articles found.

Destiny Pharma PLC

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.